Thuy Le1, Nguyen Van Kinh1, Ngo T K Cuc1, Nguyen L N Tung1, Nguyen T Lam1, Pham T T Thuy1, Do D Cuong1, Pham T H Phuc1, Vu H Vinh1, Doan T H Hanh1, Vu Van Tam1, Nguyen T Thanh1, Tran P Thuy1, Nguyen T Hang1, Hoang B Long1, Ho T Nhan1, Heiman F L Wertheim1, Laura Merson1, Cecilia Shikuma1, Jeremy N Day1, Nguyen V V Chau1, Jeremy Farrar1, Guy Thwaites1, Marcel Wolbers1. 1. From Wellcome Trust Major Overseas Programme, Oxford University Clinical Research Unit (T.L., N.T.T., T.P.T., N.T.H., H.B.L., H.T.N., H.F.L.W., J.N.D., J.F., G.T., M.W.), and the Hospital for Tropical Diseases (N.T.K.C., N.L.N.T., N.V.V.C.), Ho Chi Minh City, the National Hospital for Tropical Diseases (N.V.K., N.T.L.) and Bach Mai Hospital (P.T.T.T., D.D.C.), Hanoi, Viet Tiep Hospital, Hai Phong (P.T.H.P., V.H.V.), and Vietnam-Sweden Uong Bi Hospital, Quang Ninh (D.T.H.H., V.V.T.) - all in Vietnam; the Centre for Tropical Medicine and Global Health (T.L., J.N.D., G.T., M.W.), and the Worldwide Antimalarial Resistance Network (L.M.), University of Oxford, Oxford, United Kingdom; the Department of Medical Microbiology, Radboudumc, Nijmegen, the Netherlands (H.F.L.W.); and the Hawaii Center for AIDS, University of Hawaii at Manoa, Honolulu (T.L., C.S.).
Abstract
BACKGROUND: Talaromyces marneffei infection is a major cause of human immunodeficiency virus (HIV)-related death in South and Southeast Asia. Guidelines recommend initial treatment with amphotericin B deoxycholate, but this drug has substantial side effects, a high cost, and limited availability. Itraconazole is available in oral form, is associated with fewer unacceptable side effects than amphotericin, and is widely used in place of amphotericin; however, clinical trials comparing these two treatments are lacking. METHODS: In this open-label, noninferiority trial, we randomly assigned 440 HIV-infected adults who had talaromycosis, confirmed by either microscopy or culture, to receive either intravenous amphotericin B deoxycholate (amphotericin) (219 patients), at a dose of 0.7 to 1.0 mg per kilogram of body weight per day, or itraconazole capsules (221 patients), at a dose of 600 mg per day for 3 days, followed by 400 mg per day, for 11 days; thereafter, all the patients received maintenance therapy with itraconazole. The primary outcome was all-cause mortality at week 2. Secondary outcomes included all-cause mortality at week 24, the time to clinical resolution of talaromycosis, early fungicidal activity, relapse of talaromycosis, development of the immune reconstitution inflammatory syndrome (IRIS), and the side-effect profile. RESULTS: The risk of death at week 2 was 6.5% in the amphotericin group and 7.4% in the itraconazole group (absolute risk difference, 0.9 percentage points; 95% confidence interval [CI], -3.9 to 5.6; P<0.001 for noninferiority); however, the risk of death at week 24 was 11.3% in the amphotericin group and 21.0% in the itraconazole group (absolute risk difference, 9.7 percentage points; 95% CI, 2.8 to 16.6; P=0.006). Treatment with amphotericin was associated with significantly faster clinical resolution and fungal clearance and significantly lower rates of relapse and IRIS than itraconazole. The patients who received amphotericin had significantly higher rates of infusion-related reactions, renal failure, hypokalemia, hypomagnesemia, and anemia than patients in the itraconazole group. CONCLUSIONS: Amphotericin was superior to itraconazole as initial treatment for talaromycosis with respect to 6-month mortality, clinical response, and fungicidal activity. (Funded by the Medical Research Council and others; IVAP Current Controlled Trials number, ISRCTN59144167 .).
BACKGROUND: Talaromyces marneffei infection is a major cause of human immunodeficiency virus (HIV)-related death in South and Southeast Asia. Guidelines recommend initial treatment with amphotericin B deoxycholate, but this drug has substantial side effects, a high cost, and limited availability. Itraconazole is available in oral form, is associated with fewer unacceptable side effects than amphotericin, and is widely used in place of amphotericin; however, clinical trials comparing these two treatments are lacking. METHODS: In this open-label, noninferiority trial, we randomly assigned 440 HIV-infected adults who had talaromycosis, confirmed by either microscopy or culture, to receive either intravenous amphotericin B deoxycholate (amphotericin) (219 patients), at a dose of 0.7 to 1.0 mg per kilogram of body weight per day, or itraconazole capsules (221 patients), at a dose of 600 mg per day for 3 days, followed by 400 mg per day, for 11 days; thereafter, all the patients received maintenance therapy with itraconazole. The primary outcome was all-cause mortality at week 2. Secondary outcomes included all-cause mortality at week 24, the time to clinical resolution of talaromycosis, early fungicidal activity, relapse of talaromycosis, development of the immune reconstitution inflammatory syndrome (IRIS), and the side-effect profile. RESULTS: The risk of death at week 2 was 6.5% in the amphotericin group and 7.4% in the itraconazole group (absolute risk difference, 0.9 percentage points; 95% confidence interval [CI], -3.9 to 5.6; P<0.001 for noninferiority); however, the risk of death at week 24 was 11.3% in the amphotericin group and 21.0% in the itraconazole group (absolute risk difference, 9.7 percentage points; 95% CI, 2.8 to 16.6; P=0.006). Treatment with amphotericin was associated with significantly faster clinical resolution and fungal clearance and significantly lower rates of relapse and IRIS than itraconazole. The patients who received amphotericin had significantly higher rates of infusion-related reactions, renal failure, hypokalemia, hypomagnesemia, and anemia than patients in the itraconazole group. CONCLUSIONS: Amphotericin was superior to itraconazole as initial treatment for talaromycosis with respect to 6-month mortality, clinical response, and fungicidal activity. (Funded by the Medical Research Council and others; IVAP Current Controlled Trials number, ISRCTN59144167 .).
Authors: R S Ying; T Le; W P Cai; Y R Li; C B Luo; Y Cao; C Y Wen; S G Wang; X Ou; W S Chen; S Z Chen; P L Guo; M Chen; Y Guo; X P Tang; L H Li Journal: HIV Med Date: 2020-12 Impact factor: 3.180
Authors: Helmut J F Salzer; Rhett J Stoney; Kristina M Angelo; Thierry Rolling; Martin P Grobusch; Michael Libman; Rogelio López-Vélez; Alexandre Duvignaud; Hilmir Ásgeirsson; Clara Crespillo-Andújar; Eli Schwartz; Philippe Gautret; Emmanuel Bottieau; Sabine Jordan; Christoph Lange; Davidson H Hamer Journal: J Travel Med Date: 2018-08-01 Impact factor: 8.490
Authors: George R Thompson; Thuy Le; Ariya Chindamporn; Carol A Kauffman; Ana Alastruey-Izquierdo; Neil M Ampel; David R Andes; Darius Armstrong-James; Olusola Ayanlowo; John W Baddley; Bridget M Barker; Leila Lopes Bezerra; Maria J Buitrago; Leili Chamani-Tabriz; Jasper F W Chan; Methee Chayakulkeeree; Oliver A Cornely; Cao Cunwei; Jean-Pierre Gangneux; Nelesh P Govender; Ferry Hagen; Mohammad T Hedayati; Tobias M Hohl; Grégory Jouvion; Chris Kenyon; Christopher C Kibbler; Nikolai Klimko; David C M Kong; Robert Krause; Low Lee Lee; Graeme Meintjes; Marisa H Miceli; Peter-Michael Rath; Andrej Spec; Flavio Queiroz-Telles; Ebrahim Variava; Paul E Verweij; Ilan S Schwartz; Alessandro C Pasqualotto Journal: Lancet Infect Dis Date: 2021-08-06 Impact factor: 71.421